Skip to main content
. 2022 Mar;11(3):386–396. doi: 10.21037/tau-21-1015

Figure 3.

Figure 3

Change of proteinuria level in 34 patients with tyrosine-kinase inhibitor (TKI) and administration of programmed cell death protein 1 (PD-1) inhibitor combined treatment. After TKI treatment, proteinuria level increased. However, the administration of PD-1 inhibitor would lead to further proteinuria deterioration.